Brind.
  1. Elizabeth O’Farrell was appointed to the board of SpyGlass Pharma, which is led by CEO Patrick Mooney. Elizabeth previously gained experience at Eli Lilly.

SpyGlass Pharma Announces Positive 4-Year Trial Results for OHT Treatment

1 report, 1 independent Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

SpyGlass Pharma announced positive 4-year first-in-human trial results for the Bimatoprost Drug Pad-IOL System in patients with mild-to-moderate open angle glaucoma or ocular hypertension. The interim results showed a 37% reduction in mean intraocular pressure across all dose groups. Furthermore, 86% of patients remained off all topical IOP-lowering drops, and no product-related adverse events were reported.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The successful trial results validate the core product designed by SpyGlass Pharma for chronic eye conditions. This achievement supports the company's goal of transforming treatment paradigms through long-acting drug delivery, potentially boosting its market potential.

Elizabeth O’Farrell was appointed to the board of SpyGlass Pharma, which is led by CEO Patrick Mooney.

From manilatimes.net

Who's involved

  • SpyglassCompany that conducted the clinical trial and announced the positive results
  • Patrick MooneyResearcher and CEO of SpyGlass Pharma

Keep exploring

Part of

Elizabeth O’Farrell was appointed to the board of SpyGlass Pharma, which is led by CEO Patrick Mooney. Elizabeth previously gained experience at Eli Lilly. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped